DK168271B1 - Farmaceutiske præparater indeholdende phosphatidylserin og fremgangsmåde til fremstilling deraf - Google Patents

Farmaceutiske præparater indeholdende phosphatidylserin og fremgangsmåde til fremstilling deraf Download PDF

Info

Publication number: DK168271B1
Authority: DK; Denmark
Prior art keywords: phosphatidylserine; phosphatidylethanolamine; weight; extracted; brain tissue
Prior art date: 1983-11-17

Application number

DK524884A

Other languages

Danish (da)

English (en)

Other versions

DK524884D0 (da

DK524884A (da

Inventor

Francesco Della Valle

Aurelio Romeo

Original Assignee

Fidia Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-11-17

Filing date

1984-11-02

Publication date

1994-03-07

1984-11-02 Application filed by Fidia Spa filed Critical Fidia Spa

1984-11-02 Publication of DK524884D0 publication Critical patent/DK524884D0/da

1985-05-18 Publication of DK524884A publication Critical patent/DK524884A/da

1994-03-07 Application granted granted Critical

1994-03-07 Publication of DK168271B1 publication Critical patent/DK168271B1/da

Links

TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 title claims abstract description 128
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 title claims abstract description 128
238000002360 preparation method Methods 0.000 title claims description 50
238000000034 method Methods 0.000 title claims description 10
239000008194 pharmaceutical composition Substances 0.000 title claims description 6
230000008569 process Effects 0.000 title claims description 6
150000008104 phosphatidylethanolamines Chemical class 0.000 claims abstract description 57
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims abstract description 56
239000000203 mixture Substances 0.000 claims abstract description 55
150000003904 phospholipids Chemical class 0.000 claims abstract description 51
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 21
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 16
210000005013 brain tissue Anatomy 0.000 claims description 14
241001465754 Metazoa Species 0.000 claims description 13
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
239000003085 diluting agent Substances 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
239000002904 solvent Substances 0.000 claims 1
230000000694 effects Effects 0.000 abstract description 47
230000015271 coagulation Effects 0.000 abstract description 18
238000005345 coagulation Methods 0.000 abstract description 18
210000003169 central nervous system Anatomy 0.000 abstract description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
230000002490 cerebral effect Effects 0.000 description 18
108010094028 Prothrombin Proteins 0.000 description 12
102100027378 Prothrombin Human genes 0.000 description 12
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 12
229940039716 prothrombin Drugs 0.000 description 12
239000008103 glucose Substances 0.000 description 10
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
238000001727 in vivo Methods 0.000 description 9
241000700159 Rattus Species 0.000 description 8
230000000144 pharmacologic effect Effects 0.000 description 6
239000000243 solution Substances 0.000 description 6
208000011580 syndromic disease Diseases 0.000 description 6
230000032683 aging Effects 0.000 description 5
230000023555 blood coagulation Effects 0.000 description 5
229930000680 A04AD01 - Scopolamine Natural products 0.000 description 4
STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 4
STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 4
238000013019 agitation Methods 0.000 description 4
239000008280 blood Substances 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
208000015114 central nervous system disease Diseases 0.000 description 4
230000001684 chronic effect Effects 0.000 description 4
230000003291 dopaminomimetic effect Effects 0.000 description 4
150000002632 lipids Chemical class 0.000 description 4
239000002502 liposome Substances 0.000 description 4
239000000825 pharmaceutical preparation Substances 0.000 description 4
239000000047 product Substances 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 4
229960002646 scopolamine Drugs 0.000 description 4
208000024827 Alzheimer disease Diseases 0.000 description 3
241000283690 Bos taurus Species 0.000 description 3
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
229930195725 Mannitol Natural products 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
108010000499 Thromboplastin Proteins 0.000 description 3
102000002262 Thromboplastin Human genes 0.000 description 3
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
229960004373 acetylcholine Drugs 0.000 description 3
230000002429 anti-coagulating effect Effects 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
229940061607 dibasic sodium phosphate Drugs 0.000 description 3
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
239000003814 drug Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
239000000594 mannitol Substances 0.000 description 3
235000010355 mannitol Nutrition 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
239000012528 membrane Substances 0.000 description 3
229940045641 monobasic sodium phosphate Drugs 0.000 description 3
229910000403 monosodium phosphate Inorganic materials 0.000 description 3
235000019799 monosodium phosphate Nutrition 0.000 description 3
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 3
230000002792 vascular Effects 0.000 description 3
PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 2
108091006112 ATPases Proteins 0.000 description 2
102000057290 Adenosine Triphosphatases Human genes 0.000 description 2
102000006410 Apoproteins Human genes 0.000 description 2
108010083590 Apoproteins Proteins 0.000 description 2
208000026680 Metabolic Brain disease Diseases 0.000 description 2
206010062190 Metabolic encephalopathy Diseases 0.000 description 2
108010057464 Prolactin Proteins 0.000 description 2
102000003946 Prolactin Human genes 0.000 description 2
206010039966 Senile dementia Diseases 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
235000013871 bee wax Nutrition 0.000 description 2
239000012166 beeswax Substances 0.000 description 2
230000003542 behavioural effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
210000003710 cerebral cortex Anatomy 0.000 description 2
230000008859 change Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
239000000812 cholinergic antagonist Substances 0.000 description 2
239000000701 coagulant Substances 0.000 description 2
230000001054 cortical effect Effects 0.000 description 2
206010061428 decreased appetite Diseases 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
239000012154 double-distilled water Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000001035 drying Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000000605 extraction Methods 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
230000002267 hypothalamic effect Effects 0.000 description 2
208000014674 injury Diseases 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
210000000653 nervous system Anatomy 0.000 description 2
230000000955 neuroendocrine Effects 0.000 description 2
239000002858 neurotransmitter agent Substances 0.000 description 2
150000003905 phosphatidylinositols Chemical class 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
229940097325 prolactin Drugs 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
238000005303 weighing Methods 0.000 description 2
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
108010039209 Blood Coagulation Factors Proteins 0.000 description 1
102000015081 Blood Coagulation Factors Human genes 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
208000027776 Extrapyramidal disease Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
108090000604 Hydrolases Proteins 0.000 description 1
102000004157 Hydrolases Human genes 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
101000648554 Mus musculus Sushi domain-containing protein 6 Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
101000687509 Rattus norvegicus Prolactin Proteins 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000000578 anorexic effect Effects 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
230000006399 behavior Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
239000003114 blood coagulation factor Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
230000023852 carbohydrate metabolic process Effects 0.000 description 1
235000021256 carbohydrate metabolism Nutrition 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
230000001713 cholinergic effect Effects 0.000 description 1
230000027288 circadian rhythm Effects 0.000 description 1
230000009852 coagulant defect Effects 0.000 description 1
KAATUXNTWXVJKI-UHFFFAOYSA-N cypermethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OC(C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 KAATUXNTWXVJKI-UHFFFAOYSA-N 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
230000006744 dopaminergic deficit Effects 0.000 description 1
230000000440 effect on coagulation Effects 0.000 description 1
230000012173 estrus Effects 0.000 description 1
230000021824 exploration behavior Effects 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
230000006870 function Effects 0.000 description 1
PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
230000001933 haemocoagulation Effects 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000004922 lacquer Substances 0.000 description 1
229940041476 lactose 100 mg Drugs 0.000 description 1
210000005171 mammalian brain Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
239000003149 muscarinic antagonist Substances 0.000 description 1
SFMJNHNUOVADRW-UHFFFAOYSA-N n-[5-[9-[4-(methanesulfonamido)phenyl]-2-oxobenzo[h][1,6]naphthyridin-1-yl]-2-methylphenyl]prop-2-enamide Chemical compound C1=C(NC(=O)C=C)C(C)=CC=C1N1C(=O)C=CC2=C1C1=CC(C=3C=CC(NS(C)(=O)=O)=CC=3)=CC=C1N=C2 SFMJNHNUOVADRW-UHFFFAOYSA-N 0.000 description 1
230000014508 negative regulation of coagulation Effects 0.000 description 1
210000001577 neostriatum Anatomy 0.000 description 1
210000000944 nerve tissue Anatomy 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
230000003957 neurotransmitter release Effects 0.000 description 1
229960002748 norepinephrine Drugs 0.000 description 1
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
229930004090 phosphatidylinositide Natural products 0.000 description 1
239000006187 pill Substances 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000008307 presynaptic mechanism Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
239000000523 sample Substances 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000004904 shortening Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
230000002739 subcortical effect Effects 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
230000001026 thromboplastic effect Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
229910052719 titanium Inorganic materials 0.000 description 1
239000010936 titanium Substances 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J7/00—Phosphatide compositions for foodstuffs, e.g. lecithin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Food Science & Technology (AREA)
Neurosurgery (AREA)
Dispersion Chemistry (AREA)
Neurology (AREA)
Polymers & Plastics (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Heat Treatment Of Steel (AREA)
Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Epoxy Resins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

DK524884A 1983-11-17 1984-11-02 Farmaceutiske præparater indeholdende phosphatidylserin og fremgangsmåde til fremstilling deraf DK168271B1 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT4935583		1983-11-17
IT49355/83A IT1212900B (it)	1983-11-17	1983-11-17	Uso terapeutico della fosfatidilserina in malattie del sistema nervoso centrale senza effetti sulla coagulazione sanguigna

Publications (3)

Publication Number	Publication Date
DK524884D0 DK524884D0 (da)	1984-11-02
DK524884A DK524884A (da)	1985-05-18
DK168271B1 true DK168271B1 (da)	1994-03-07

Family

ID=11270453

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK524884A DK168271B1 (da)	1983-11-17	1984-11-02	Farmaceutiske præparater indeholdende phosphatidylserin og fremgangsmåde til fremstilling deraf

Country Status (25)

Country	Link
US (1)	US4595680A (it)
EP (1)	EP0148045B1 (it)
JP (1)	JPH0676334B2 (it)
KR (1)	KR870001330B1 (it)
AT (1)	ATE35415T1 (it)
AU (1)	AU572228B2 (it)
BE (1)	BE901074A (it)
CH (1)	CH661734A5 (it)
DE (1)	DE3472406D1 (it)
DK (1)	DK168271B1 (it)
ES (1)	ES8608528A1 (it)
FI (1)	FI79946C (it)
FR (1)	FR2555050B1 (it)
GR (1)	GR80951B (it)
HU (1)	HU193302B (it)
IE (1)	IE58130B1 (it)
IL (1)	IL73420A (it)
IN (1)	IN162717B (it)
IT (1)	IT1212900B (it)
LU (1)	LU85639A1 (it)
MX (1)	MX160792A (it)
NO (1)	NO164275C (it)
NZ (1)	NZ210091A (it)
PT (1)	PT79510B (it)
ZA (1)	ZA848776B (it)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2471776A1 (fr) *	1979-12-21	1981-06-26	Oreal	Nouveaux agents cosmetiques a base de polymeres cationiques, compositions cosmetiques les contenant, et leur application
IT1213034B (it) *	1986-02-12	1989-12-07	Istituto Chemioterapico Di Lod	Composizioni farmaceutiche per la terapia di cerebropatie su base organica e funzionale.
US5314695A (en) *	1990-11-13	1994-05-24	Corvas International, Inc.	Tissue factor based prothrombin time reagent
FR2673512B1 (fr) *	1991-03-05	1993-08-20	Inst Rech Biolog Sa	Nouvelles compositions dietetiques a base de lipides complexes phosphores et leur utilisation dans les troubles du sommeil.
IT1247165B (it) *	1991-03-15	1994-12-12	Fidia Spa	Uso terapeutico della fosfatidilserina e derivati in patologie degenerative anche associate a disfunsioni immunitarie.
IT1248012B (it) *	1991-06-07	1995-01-05	Mediolanum Farmaceutici Spa	Impiego del fosfatidilinositolo per la terapia dei disturbi della depressione.
IT1260149B (it) *	1992-04-17	1996-03-28	Fidia Spa	Metodo per la preparazione e purificazione di miscele di fosfolipidi prive di contaminanti da virus non convenzionali
GB9621293D0 (en) *	1996-10-11	1996-11-27	Scotia Holdings Plc	Formulations containing unsaturated fatty acids
US20030147944A1 (en) *	1999-12-10	2003-08-07	Mayer Lawrence D	Lipid carrier compositions with protected surface reactive functions
US7226916B1 (en) *	2000-05-08	2007-06-05	N.V. Nutricia	Preparation for the prevention and/or treatment of vascular disorders
TWI281407B (en) *	2000-09-18	2007-05-21	Vasogen Ireland Ltd	Apoptosis-mimicking synthetic entities and use thereof in medical treatment
CA2319928A1 (en)	2000-09-18	2002-03-18	Vasogen Ireland Limited	Apoptosis-mimicking synthetic entities and use thereof in medical treatments
US6676963B1 (en) *	2000-10-27	2004-01-13	Barnes-Jewish Hospital	Ligand-targeted emulsions carrying bioactive agents
KR100680121B1 (ko) *	2001-08-09	2007-02-07	데구사 푸드 인그리디언츠 게엠베하	(리소-)포스파티딜세린을 포함하는 온혈동물에서 스트레스상태의 예방 및 치료용 제제
EP1503742A2 (de) *	2002-04-19	2005-02-09	Bioghurt Biogarde GmbH & Co. KG.	Matrix mit einer bioaktiven phospholipid-haltigen komponente
US6878532B1 (en)	2003-04-28	2005-04-12	Sioux Biochemical, Inc.	Method of producing phosphatidylserine
CN1308334C (zh) *	2004-06-01	2007-04-04	山东师范大学	一种从动物脑提取磷脂酰丝氨酸的方法
IL182372A0 (en) *	2007-04-01	2008-01-20	Enzymotec Ltd	Compositions containing phosphatidylserine in treating diabetes-associated conditions
ITMI20121784A1 (it) *	2012-10-22	2014-04-23	Velleja Res Srl	Composizioni galattogeniche a base di fosfatidilserina
US20160317560A1 (en) *	2013-11-07	2016-11-03	The University Of North Carolina At Chapel Hill	Particles containing phospholipids or bioactive fatty acids and uses thereof
IT202100032252A1 (it) *	2021-12-22	2023-06-22	Fidia Farm Spa	Processo di estrazione e purificazione industriale di fosfolipidi

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3156616A (en) *	1958-11-14	1964-11-10	Canada Majesty In Right Of	Composition and method for correcting foods and blood conditions having clot promoting characteristics
US3436413A (en) *	1965-12-21	1969-04-01	Canada Packers Ltd	Process for the isolation of phosphatidyl serine
FR5060M (it) *	1965-12-22	1967-05-08
US4078052A (en) *	1976-06-30	1978-03-07	The United States Of America As Represented By The Secretary Of Health, Education And Welfare	Large unilamellar vesicles (LUV) and method of preparing same
JPS55115824A (en) *	1979-02-28	1980-09-06	Nippon Shoji Kk	Remedy for clouding of consciousness and sensomobile disorder

1983
- 1983-11-17 IT IT49355/83A patent/IT1212900B/it active
1984
- 1984-04-12 US US06/599,341 patent/US4595680A/en not_active Expired - Fee Related
- 1984-10-30 IE IE278584A patent/IE58130B1/en not_active IP Right Cessation
- 1984-11-02 IN IN767/CAL/84A patent/IN162717B/en unknown
- 1984-11-02 NZ NZ210091A patent/NZ210091A/xx unknown
- 1984-11-02 DK DK524884A patent/DK168271B1/da not_active IP Right Cessation
- 1984-11-05 IL IL73420A patent/IL73420A/xx not_active IP Right Cessation
- 1984-11-09 ZA ZA848776A patent/ZA848776B/xx unknown
- 1984-11-12 ES ES537575A patent/ES8608528A1/es not_active Expired
- 1984-11-13 LU LU85639A patent/LU85639A1/fr unknown
- 1984-11-13 FR FR8417262A patent/FR2555050B1/fr not_active Expired
- 1984-11-14 FI FI844468A patent/FI79946C/fi not_active IP Right Cessation
- 1984-11-15 GR GR80951A patent/GR80951B/el unknown
- 1984-11-15 JP JP59242174A patent/JPH0676334B2/ja not_active Expired - Lifetime
- 1984-11-15 CH CH5471/84A patent/CH661734A5/fr not_active IP Right Cessation
- 1984-11-15 MX MX203403A patent/MX160792A/es unknown
- 1984-11-16 EP EP84402340A patent/EP0148045B1/en not_active Expired
- 1984-11-16 PT PT79510A patent/PT79510B/pt not_active IP Right Cessation
- 1984-11-16 NO NO844585A patent/NO164275C/no unknown
- 1984-11-16 AT AT84402340T patent/ATE35415T1/de not_active IP Right Cessation
- 1984-11-16 BE BE0/214020A patent/BE901074A/nl not_active IP Right Cessation
- 1984-11-16 DE DE8484402340T patent/DE3472406D1/de not_active Expired
- 1984-11-16 AU AU35630/84A patent/AU572228B2/en not_active Ceased
- 1984-11-16 HU HU844269A patent/HU193302B/hu not_active IP Right Cessation
- 1984-11-17 KR KR1019840007230A patent/KR870001330B1/ko not_active IP Right Cessation

Also Published As

Publication number	Publication date
FR2555050A1 (fr)	1985-05-24
IL73420A0 (en)	1985-02-28
ATE35415T1 (de)	1988-07-15
CH661734A5 (fr)	1987-08-14
AU572228B2 (en)	1988-05-05
HUT35957A (en)	1985-08-28
ES537575A0 (es)	1986-07-16
FI844468A0 (fi)	1984-11-14
JPH0676334B2 (ja)	1994-09-28
GR80951B (en)	1984-12-18
IE58130B1 (en)	1993-07-14
NO844585L (no)	1985-05-20
IE842785L (en)	1985-05-17
IN162717B (it)	1988-07-02
LU85639A1 (fr)	1985-06-04
FI844468L (fi)	1985-05-18
BE901074A (nl)	1985-05-17
NZ210091A (en)	1988-06-30
PT79510A (en)	1984-12-01
IT1212900B (it)	1989-11-30
ZA848776B (en)	1986-06-25
IL73420A (en)	1988-06-30
AU3563084A (en)	1985-05-30
MX160792A (es)	1990-05-17
HU193302B (en)	1987-09-28
DE3472406D1 (en)	1988-08-04
PT79510B (en)	1986-09-08
FI79946B (fi)	1989-12-29
EP0148045A1 (en)	1985-07-10
EP0148045B1 (en)	1988-06-29
IT8349355A0 (it)	1983-11-17
NO164275B (no)	1990-06-11
DK524884D0 (da)	1984-11-02
KR850003504A (ko)	1985-06-20
DK524884A (da)	1985-05-18
US4595680A (en)	1986-06-17
JPS60132921A (ja)	1985-07-16
KR870001330B1 (ko)	1987-07-18
ES8608528A1 (es)	1986-07-16
FR2555050B1 (fr)	1986-12-26
NO164275C (no)	1990-09-19
FI79946C (fi)	1990-04-10

Legal Events

Date	Code	Title	Description
1994-03-07	B1	Patent granted (law 1993)
1995-07-24	PBP	Patent lapsed

Publication	Publication Date	Title
DK168271B1 (da)	1994-03-07	Farmaceutiske præparater indeholdende phosphatidylserin og fremgangsmåde til fremstilling deraf
US5506218A (en)	1996-04-09	Methods useful in endotoxin based therapy
US7084126B1 (en)	2006-08-01	Methods and compositions for enhancing cellular function through protection of tissue components
US8877239B2 (en)	2014-11-04	Lipid supplements for maintaining health and treatment of acute and chronic disorders
DE286011T1 (de)	1989-03-09	Natuerliches oberflaechenwirksames lungenpraeparat, verfahren zu seiner herstellung und pharmazeutische zusammensetzungen.
JPS6241688B2 (it)	1987-09-04
Klipp et al.	2018	EL20, a potent antiarrhythmic compound, selectively inhibits calmodulin-deficient ryanodine receptor type 2
JPS6284028A (ja)	1987-04-17	膜流動化のための脂質混合物
JP5968878B2 (ja)	2016-08-10	イソアクテオシドまたはその製薬上許容される塩の使用
US20030050283A1 (en)	2003-03-13	Composition for the treatment and/or prevention of macular degeneration, method for its manufacture, and its use for treating the eye
Drenckhahn et al.	1979	Experimental myopathy induced by amphiphilic cationic compounds including several psychotropic drugs
EP0201623B1 (en)	1990-02-07	Pharmaceutical compositions for the treatment of involutional brian syndromes and mental decay
WO1989009600A1 (en)	1989-10-19	Method and composition for treating neurological disorders
WO1980001456A1 (en)	1980-07-24	Pharmaceutical composition and process for the preparation thereof
US20040204383A1 (en)	2004-10-14	Lysophosphatidic acid analogs and inhibition of neointima formation
EP0468327B1 (en)	1996-11-20	Oral pharmaceutical compositions containing hirudin
EP0217258A2 (en)	1987-04-08	The use of choline or choline releasing compounds in the production of pharmacological compositions capable of reducing fatigue
CA1235659A (en)	1988-04-26	Pharmaceutical compositions and method for preparing phosphatidylserine compositions useful in treating central nervous system disorders without effects on blood coagulation
Hall et al.	1976	Peripheral neuropathy complicating primary hyperoxaluria
JP2022521119A (ja)	2022-04-06	組織の灌流の増加における使用のためのイノシトールリン酸化合物
CA2091980C (en)	1996-12-17	Natural pulmonary surfactants and lipid extracts thereof
WO2023119129A1 (en)	2023-06-29	Industrial process for the extraction and purification of phospholipids
CN118475354A (zh)	2024-08-09	用于提取和纯化磷脂的工业方法
JP2007106679A (ja)	2007-04-26	血液凝固反応促進剤
JP5570172B2 (ja)	2014-08-13	喫煙による循環機能不全の予防／改善または治療剤